2/15/2022

speaker
Shannon
Conference Operator

Good morning. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to NMED's second quarter fiscal 2022 financial results and business update conference call for the period ended December 31st, 2021. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, press the pound key. Thank you. Mr. Clancy, you may begin your conference.

speaker
Colin Clancy
Senior Director of Investor Relations

Thank you, Shannon, and good day, ladies and gentlemen. My name is Colin Clancy, INMED Senior Director of Investor Relations. Welcome to INMED's second quarter fiscal 2022 financial results and business update conference call. Please note our speakers are joining today from remote locations, so we appreciate your patience if we encounter any unexpected technical challenges. Before we begin, we'd like to go over our disclosure statements. followed by an update on our health and wellness commercial activities, together with a progress update on our pharmaceutical drug development programs, which will be led by our President and CEO, Eric Adams. Mr. Bruce Caldwell, our Chief Financial Officer, will then review the financial results of operations. Following that, we will be available for questions and answer sessions. Also joining us today to address your questions will be Eric Hsu, Senior Vice President of Preclinical Research and Development, Alexandra Mancini, Senior Vice President, Clinical and Regulatory Affairs, Shane Johnson, Senior Vice President and General Manager of BayMedica, and Michael Woodenberg, Vice President of Chemistry, Manufacturing, and Controls. Please be advised that certain statements in the following conference call include expectations for in-meds business operations, clinical development, key personnel, contractual arrangements, regulatory approvals, revenue opportunities, financing, and cash runway all constitute forward-looking statements. Such statements are not historical facts, but rather predictions about the future, which inherently involve assumptions, risks, and uncertainties. Actual results may differ materially from those contained in the forward-looking statements. A description of these risks can be found in our latest disclosure documents. NMED does not undertake any obligation to update any forward-looking statements during this call. I would like now to turn it over to NMED's President and CEO, Eric Adams. Eric?

speaker
Eric Adams
President and CEO

Thanks, Colin, and thank you everyone for joining us today. Since our last earnings call, we've made some significant advancements, and these are advancements that we believe have positioned InMed to be a clear leader in the rare cannabinoid space, offering a unique value proposition and investment opportunity across both the pharmaceutical and health and wellness markets. Most notably, in October, the company completed the acquisition of BayMedica, a U.S.-based company that specializes in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector, establishing NMED as a global leader in the research, development, manufacturing, and commercialization of rare cannabinoids. Since the acquisition, we have been intently focused on ensuring an expedited integration in order to accelerate commercial activities, including product launches, with the end goal of driving revenues in the near term. While this acquisition provides us with access to the consumer health and wellness markets, we remain a pharmaceutical company at our core. Our pharmaceutical drug development programs continue to advance in both preclinical and clinical studies, supporting sequential value creation for our shareholders as we continue to hit important milestones in drug development. We now offer shareholders the combination of near two-term revenue generation combined with a longer-term value proposition associated with our pharmaceutical drug development programs. Let me start by addressing our short-term plans for commercial operations. Since closing the acquisition of BayMedica in October, our primary focus has been ensuring the smooth integration of both teams and developing an aggressive commercial plan for the coming year. BayMedica's focus is on the business-to-business, or B2B, supply of rare cannabinoids to the consumer health and wellness markets, including nutraceuticals, cosmetics, functional food and beverages, as well as animal health markets. From a commercial perspective, our primary goals for the BayMedica business over the next few quarters include launching new products to build a robust product portfolio of rare cannabinoids, increase revenues and margins from new and existing products through B2B sales, enhance the sales and marketing infrastructure to support anticipated growth, improve margins through the technical improvements and scale-up efficiencies, develop new cannabinoid analogs for potential lead molecule identification for pharmaceutical applications. These priorities reflect the importance of developing a robust product offering, which in turn is key to attracting a larger customer base and gaining market share. In January, we launched a second rare cannabinoid, CBT, and have commenced initial B2B sales to customers within the health and wellness markets. We also have several other rare cannabinoids at different stages of development and expect to roll out additional in-demand products over the coming months. We are very excited about our next two non-intoxicating products, which are CBDV and THCV, which will be coming to market shortly. We are currently working with our third-party manufacturers to produce large-scale batches to support initial demand over the coming months. As this is still a very nascent industry, it is difficult to predict the demand. However, through market research and speaking with our existing customer base, we believe that both of these products are in very high demand. Current market prices of these products range from approximately $17,000 to $30,000 per kilogram. Given our cost structure at large-scale commercial production, we believe we can be competitive on pricing while maintaining attractive margins. BayMedica currently leads the industry in large batch production of its first non-intoxicating rare cannabinoid, CBC, or cannabichromine, with current batch sizes of more than 200 kilograms and with the ability to increase to metric ton quantities as market demand increases. This expertise is something we will replicate in bringing our next products to market. As I mentioned, pipeline development is a key priority for the company. In addition to CBDV and THCV, BayMedica has several other high-value rare cannabinoids at various stages of development and scale-up, including CBL and CBGV. Our commercial strategy is to focus on high-demand, attractive margin products rather than compounds that are readily commoditized and with very low prices, such as CBD. As the company continues to grow and add to our product portfolio, it's important to build out an appropriate sales and marketing infrastructure. The company announced today the hiring of Jerry Griffin, as Vice President of Sales and Marketing at BayMedica. Jerry comes with a wealth of experience across various markets and with numerous cannabinoid products. He has a proven track record as a seasoned sales executive who has held several senior-level roles at cannabinoid-based companies, including most recently at a competitor company where he was Vice President of Sales and Business Development. The appointment of Jerry reaffirms our commitment to accelerate the company's commercial plans and grow market share in this burgeoning industry. We have seen over the last year that there is growing interest in rare cannabinoids for their potential therapeutic properties. Health and wellness companies are looking to rare cannabinoids for their potential physiological effects beyond more common cannabinoids, such as CBD, as well as to further differentiate their products. Very few companies can produce rare cannabinoids at commercial scale, and we are one of them. we believe we are well positioned to take an early lead as a supplier of high quality rare cannabinoids in this rapidly growing market. As this is a relatively new market segment, we understand research and education is key to building awareness and understanding the potential benefits of cannabinoids. An example of both the growing interest in cannabinoids as well as building up the body of research is the recent announcement that the NFL is awarding $1 million towards research into cannabinoid effects. Next, I'd like to turn to our manufacturing capabilities. With the acquisition of Baymatica, NMET now has access to multiple cannabinoid manufacturing approaches. This gives us the flexibility to select the most cost-effective method to produce a specific cannabinoid. All three of our manufacturing approaches, chemical synthesis, biosynthesis, and Integrison, can produce high quality and pure cannabinoids in a consistent manner for different applications. Our team has been working closely with our contract manufacturing and development collaborator, Allmac, on scaling up to larger batch sizes using the Integrison process in advance of commercial scale production. To further advance the Integrison scale up, we are targeting production of a pilot batch in the first half of 2022 to further verify the process with the aim of demonstrating larger scale viability at our industry-leading cannabinoid yield. Now we'll turn to the therapeutic programs, starting with INM755 for epidermolysis bullosa, or EV. The INM75 cannabinol cream is a topical cream in development for EV, a devastating genetic skin disease. Since our last call, we have commenced a phase two clinical trial of INM-755. The 755-201-EB study is designed to enroll up to 20 patients. INMED will evaluate the safety of INM-755 cannabinol creatine and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period. All four subtypes of inherited EB, which are EB simplex, dystrophic EB, junctional EB, and Kindler syndrome, are eligible for the study. The study is using a within-patient double-blind design whereby matched indexed areas will be randomized to receive the cream or a vehicle cream as a control. The study is planned to include 13 sites across eight countries in Austria, Germany, Greece, France, Italy, Israel, Serbia, and Spain. Five clinical sites have been fully activated Enrollment and patient treatment began in December 2021 and is anticipated to complete during this calendar year. This Phase II trial marks the first time that CBN, a rare cannabinoid, has been studied in a Phase II clinical trial. Turning now to INM 088. 088 is a topical eye formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient in 088 is cannabinol or CBN, the same active ingredient as in the INM 755 program. In December, we announced that a peer-reviewed scientific article entitled Cannabinol Modulates Neuroprotection and Interocular Pressure, a Potential Multi-Target Therapeutic Intervention for Glaucoma has been published in a leading international journal. These studies resulted in two key findings. CBN may promote neuroprotection of cells in the retina that are responsible for vision. And second, CBN may normalize interocular pressure. The article also reports on the comparison of CBN with other cannabinoids, including CBD and THC, with results indicating that CBN has a stronger effect and broader neuroprotective therapeutic range. These observations support the therapeutic potential for CBN in the treatment of glaucoma. The company is now preparing for a pre-IND meeting with the FDA in the coming weeks, and we continue to work towards completing the necessary preclinical studies in anticipation of filing in the first half of calendar year 2023 for regulatory permission to initiate human clinical trial. Looking now at some of our patents, I think it's important to point out that our pharmaceutical program also includes exploring other rare cannabinoids for their therapeutic effects. In November, we filed an international patent application seeking commercial exclusivity for the potential treatment of important neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and others, by demonstrating neural protection and promotion of neurite outgrowth in a population of affected neurons using a new rare cannabinoid. Another key asset from the BayMedica acquisition is their library of novel, rare cannabinoid analogs. They have several novel analogs which we intend to evaluate for use in future therapeutic programs. There's many benefits of using these novel analogs, one of which is that new chemical entities can be patented to protect their eventual commercialization, unlike naturally occurring cannabinoids identified in the plant where a patent covering the underlying molecule cannot be filed. This adds an additional level of IP protection to our current strategy and enhances future partnering opportunities. Considering the commercial importance of these analogs, this is an area where we intend to place enhanced focus in the coming years. I want to touch briefly also on the impact of COVID. As with most businesses, the global pandemic has started to impact several facets of NMID's activities. Global supply disruptions relating to resources such as raw material availability and staffing issues have directly affected development timelines for our manufacturing campaigns. Our clinical EV program has also been affected by staffing issues which have impacted patient enrollment. As a consequence, the timelines on certain programs have been slightly delayed. We continue to work with our external partners to limit any disruptions and ensure our programs continue to advance despite these global headwinds. And now just briefly turning to the outlook. In summary, over the course of the last quarter, we have continued to make considerable progress advancing our different programs. Over the next few months, shareholders should expect to see the following catalysts. Number one, product launches. We'll be bringing new products to the health and wellness market, and this is one of the company's key priorities over the coming months. Number two, updates on the Phase II clinical trial in EB. Number three, Further execution on our patent strategy, including our proprietary analogs. And four, scaling Integrison to larger batch sizes in advance of commercial scale production. Before handing the call over to Bruce, I would like to take the opportunity to welcome Ms. Janet Grove to our board of directors. Janet has significant skills and experience in providing strategic, legal, and business development advice accumulated during an impressive 30-year career in the biotech industry. Ms. Grove is a partner at Norton Rose Fulbright, and is currently the head of their Canadian Life Sciences and Healthcare Industry Practice. I'd also like to recognize Catherine Sazanov, who is stepping down from the board for personal reasons. Ms. Sazanov has served on the board since July 2019, during which time her business development and legal experience has been instrumental in navigating several key strategic initiatives for the company. On behalf of the company and shareholders, we thank her deeply for her significant contributions and dedication over the last few years. On that note, I'd like to turn the call over to our CFO, Bruce Cowell, to provide more information on our capital plans and for a review of our second quarter fiscal 2022 financials. Bruce?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-